[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"moducare\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:moducare":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100622152","moducare-versus-wait-and-see-approach-for-histologically-proven-low-grade-cervical-intraepithelial-neoplasia-cin1-100622152",false,"NCT07379905","MODUCARE Versus Wait-and-See Approach for Histologically Proven Low-grade Cervical Intraepithelial Neoplasia (CIN1)","A Randomized Trial of MODUCARE Versus Wait-and-See Approach for Histologically Proven Low-grade Cervical Intraepithelial Neoplasia (CIN1)","MODUCIN1","Inclusion Criteria:\n\n* Histologically proven CIN1\n* Any HPV status (negative, positive: high or low risk)\n* Any Pap test result\n* Age 18 - 85 years old\n* ECOG Performance status 0 - 1\n\nExclusion Criteria:\n\n* Pregnancy\n* Low likelihood of patient compliance to treatment protocol and follow-up\n* Previous operation to the cervix\n* Previous pelvic malignancy\n* Pre-existing histologically proven CIN1 \\> 12 months\n* Pre-existing histologically proven CIN2 and\u002For CIN3\n* Hypersensitivity to trial medication",true,"FEMALE","18 Years","85 Years",{"count":22,"type":23},182,"ESTIMATED","INTERVENTIONAL",[26],"NA","MODUCIN-1 (MODUcare for CIN1) is a prospective, single center, open-label, randomized trial that its purpose is to compare MODUCARE versus Wait-and-See Approach for the regression rate of histologically proven low-grade Cervical Intraepithelial Neoplasia (CIN1).",[29,30],"Low-grade Cervical Intraepithelial Neoplasia","Moducare","NOT_YET_RECRUITING","2026-02-03",{"date":34,"type":35},"2026-02-05","ACTUAL",{"date":37,"type":23},"2026-03-01",{"date":39,"type":23},"2028-03-01",{"name":41,"class":42},"Aristotle University Of Thessaloniki","OTHER"]